USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
VASCULAR PHARMACEUTICALS
Address:
1088 KNOLLRIDGE RD
BURLINGTON, NC 27217-
Phone:
N/A
URL:
N/A
EIN:
120397286
DUNS:
601953974
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
STTR Phase I $383,173.00 2
STTR Phase II $1,218,285.00 1

Award List:

Development of a Novel Method for Inhibiting Atherosclerosis in Diabetes

Award Year / Program / Phase:
2009 / STTR / Phase II
Award Amount:
$1,218,285.00
Agency:
HHS
Principal Investigator:
David R. Clemmons
Research Institution:
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The long term objective of the proposed studies is to develop a monoclonal antibody that can be administered safely to patients with diabetes that will inhibit atherosclerosis. Insulin-like growth factor-I has been impl icated in the initiation of the… More

Development of a novel method for inhibiting diabetic retinopathy

Award Year / Program / Phase:
2012 / STTR / Phase I
Award Amount:
$172,913.00
Agency:
HHS
Principal Investigator:
David R. Clemmons – 919-966-4735
Research Institution:
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The long-term objective of the proposed study is to develop a monoclonal antibody that inhibits the progression of diabetic retinopathy. Insulin-like growth factor-I (IGF-I) has been implicated in both endothelial dysfunction as well as the proliferative phase of… More